FLT3 and acute myeloid leukemia: Although the ELN does not currently recommend the use of FLT3‐ITD mutations in the analysis of MRD due to the unstable nature of these mutations,7 assessment of mutation clearance in patients receiving these therapies will be an important determinant of response durability in patients who achieve remission as the use of highly specific agents against FLT3 and other leukemic targets becomes more prevalent in AML.6, 9